Ferdinandos Skoulidis
Papers
1
Total Citations
28
H-Index
1
About
Ferdinandos Skoulidis is a leading translational researcher in thoracic oncology, whose work has fundamentally reshaped the understanding and treatment of KRAS-mutant non-small cell lung cancer (NSCLC). His major contributions center on elucidating the molecular heterogeneity of KRAS-driven tumors, particularly the distinct biology and therapeutic vulnerabilities of the KRAS G12C subtype. Skoulidis was instrumental in defining the co-mutation landscape of KRAS-mutant lung cancer, identifying STK11/LKB1 and KEAP1 alterations as critical drivers of immune evasion and poor outcomes. This foundational work directly informed the clinical development of KRAS G12C inhibitors like sotorasib, for which he led pivotal translational analyses. His impact is reflected in his highly cited publications, including the landmark 2015 *Cancer Discovery* paper on the molecular subtypes of KRAS-mutant NSCLC, which has garnered over 1,000 citations. Beyond his laboratory insights, Skoulidis is a key investigator in practice-changing clinical trials, such as the NEOSTAR study evaluating neoadjuvant immunotherapy in resectable NSCLC. His research bridges deep mechanistic discovery with immediate clinical application, making him a pivotal figure in the modern era of precision oncology for lung cancer.
Research Focus
Key Achievements
Top Papers
- 1